MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 571605 | Name: MBS Crosslinker
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

MBS crosslinker (m-Maleimidobenzoyl-N-hydroxysuccinimide ester) is a non-cleavable, water insoluble, heterobifunctional protein crosslinking reagent that is commonly used to crosslink haptens to carrier proteins and enzymes to antibody. The MBS crosslinking reagent's NHS ester and maleimide reactive groups react with amino and sulfhydryl moites, respectively. Sulfo-MBS crosslinker is the water soluble analog of MBS protein crosslinker and is a convenient choice if you do not wish to use organic solvents to solubilize MBS protein crosslinking reagent. The MBS protein crosslinker extended spacer arm analog is SMPB crosslinker SATA Protein Modifier can be used to add sulfhydryl groups (thiols, -SH) to proteins or peptides prior to MBS crosslinking.

Chemical Structure

MBS Crosslinker
MBS Crosslinker
CAS#58626-38-3

Theoretical Analysis

MedKoo Cat#: 571605

Name: MBS Crosslinker

CAS#: 58626-38-3

Chemical Formula: C15H10N2O6

Exact Mass: 314.0539

Molecular Weight: 314.25

Elemental Analysis: C, 57.33; H, 3.21; N, 8.91; O, 30.55

Price and Availability

Size Price Availability Quantity
250mg USD 350.00 2 weeks
1g USD 750.00 2 weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
MBS Crosslinker, MBS protein crosslinker
IUPAC/Chemical Name
3-Maleimidobenzoic acid N-hydroxysuccinimide ester
InChi Key
LLXVXPPXELIDGQ-UHFFFAOYSA-N
InChi Code
InChI=1S/C15H10N2O6/c18-11-4-5-12(19)16(11)10-3-1-2-9(8-10)15(22)23-17-13(20)6-7-14(17)21/h1-5,8H,6-7H2
SMILES Code
O=C(ON1C(CCC1=O)=O)C2=CC=CC(N3C(C=CC3=O)=O)=C2
Appearance
Solid powder
Purity
>97% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
MBS crosslinker (m-Maleimidobenzoyl-N-hydroxysuccinimide ester) is a non-cleavable, water insoluble, heterobifunctional protein crosslinking reagent that is commonly used to crosslink haptens to carrier proteins and enzymes to antibody.
In vitro activity:
When Paracoccus denitrificans membranes were treated with a crosslinker, m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS), a cross-linked product of M(r) approximately 31 kDa was found which reacted with antibodies against the hydrophobic subunit Nqo7 and the connector subunit Nqo6. MBS treatment of the E. coli membranes generated the 31 kDa band as in the Paracoccus membranes. Reference: FEBS Lett. 2001 Nov 23;508(3):385-8. https://pubmed.ncbi.nlm.nih.gov/11728457/
In vivo activity:
Anti-PEA antibody was obtained by immunizing mice with an antigen conjugated with mercaptosuccinyl bovine serum albumin using m-maleimidobenzoyl-N-hydroxysulfosuccinimide ester (MBS). The anti-PEA antibody showed high affinity for benzoyl PEA. The values of plasma PEA levels measured by this ELISA were comparable to those measured by HPLC, and a strong correlation was observed between the values determined by the two methods. Reference: Anal Biochem. 2022 Dec 15;659:114952. https://pubmed.ncbi.nlm.nih.gov/36228715/

Preparing Stock Solutions

The following data is based on the product molecular weight 314.25 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Di Bernardo S, Yagi T. Direct interaction between a membrane domain subunit and a connector subunit in the H(+)-translocating NADH-quinone oxidoreductase. FEBS Lett. 2001 Nov 23;508(3):385-8. doi: 10.1016/s0014-5793(01)03111-8. PMID: 11728457. 2. Cruz LJ, Iglesias E, Aguilar JC, Quintana D, Garay HE, Duarte C, Reyes O. Study of different coupling agents in the conjugation of a V3-based synthetic MAP to carrier proteins. J Pept Sci. 2001 Sep;7(9):511-8. doi: 10.1002/psc.336. PMID: 11587190. 3. Saita T, Kataoka H, Sogawa R, Hayama T, Tomita R, Monji A, Mizoguchi Y, Shimanoe C. Development of an enzyme-linked immunosorbent assay for the quantification of O-Phosphoethanolamine in human plasma. Anal Biochem. 2022 Dec 15;659:114952. doi: 10.1016/j.ab.2022.114952. Epub 2022 Oct 11. PMID: 36228715.
In vitro protocol:
1. Di Bernardo S, Yagi T. Direct interaction between a membrane domain subunit and a connector subunit in the H(+)-translocating NADH-quinone oxidoreductase. FEBS Lett. 2001 Nov 23;508(3):385-8. doi: 10.1016/s0014-5793(01)03111-8. PMID: 11728457. 2. Cruz LJ, Iglesias E, Aguilar JC, Quintana D, Garay HE, Duarte C, Reyes O. Study of different coupling agents in the conjugation of a V3-based synthetic MAP to carrier proteins. J Pept Sci. 2001 Sep;7(9):511-8. doi: 10.1002/psc.336. PMID: 11587190.
In vivo protocol:
1. Saita T, Kataoka H, Sogawa R, Hayama T, Tomita R, Monji A, Mizoguchi Y, Shimanoe C. Development of an enzyme-linked immunosorbent assay for the quantification of O-Phosphoethanolamine in human plasma. Anal Biochem. 2022 Dec 15;659:114952. doi: 10.1016/j.ab.2022.114952. Epub 2022 Oct 11. PMID: 36228715.
1: Hansen PR. Peptide-Carrier Conjugation. Methods Mol Biol. 2015;1348:51-7. doi: 10.1007/978-1-4939-2999-3_6. PubMed PMID: 26424262. 2: Xue X, Li D, Yu J, Ma G, Su Z, Hu T. Phenyl linker-induced dense PEG conformation improves the efficacy of C-terminally monoPEGylated staphylokinase. Biomacromolecules. 2013 Feb 11;14(2):331-41. doi: 10.1021/bm301511w. Epub 2013 Jan 18. PubMed PMID: 23301655. 3: Söllner T, Rassow J, Wiedmann M, Schlossmann J, Keil P, Neupert W, Pfanner N. Mapping of the protein import machinery in the mitochondrial outer membrane by crosslinking of translocation intermediates. Nature. 1992 Jan 2;355(6355):84-7. PubMed PMID: 1530986. 4: Kühn-Hölsken E, Lenz C, Dickmanns A, Hsiao HH, Richter FM, Kastner B, Ficner R, Urlaub H. Mapping the binding site of snurportin 1 on native U1 snRNP by cross-linking and mass spectrometry. Nucleic Acids Res. 2010 Sep;38(16):5581-93. doi: 10.1093/nar/gkq272. Epub 2010 Apr 26. PubMed PMID: 20421206; PubMed Central PMCID: PMC2938196. 5: Bartegi A, Roustan C, Bertrand R, Kassab R, Fattoum A. Interaction of caldesmon with actin subdomain-2. Eur J Biochem. 1998 Jun 15;254(3):571-9. PubMed PMID: 9688268. 6: Walker LM, Sack FD. Microfilament distribution in protonemata of the moss Ceratodon. Protoplasma. 1995;189(3-4):229-37. PubMed PMID: 11539384. 7: Chen F, Nielsen S, Zenobi R. Understanding chemical reactivity for homo- and heterobifunctional protein cross-linking agents. J Mass Spectrom. 2013 Jul;48(7):807-12. doi: 10.1002/jms.3224. PubMed PMID: 23832936. 8: Cruz LJ, Iglesias E, Aguilar JC, Quintana D, Garay HE, Duarte C, Reyes O. Study of different coupling agents in the conjugation of a V3-based synthetic MAP to carrier proteins. J Pept Sci. 2001 Sep;7(9):511-8. PubMed PMID: 11587190. 9: Di Bernardo S, Yagi T. Direct interaction between a membrane domain subunit and a connector subunit in the H(+)-translocating NADH-quinone oxidoreductase. FEBS Lett. 2001 Nov 23;508(3):385-8. PubMed PMID: 11728457. 10: Jones MN. Use of liposomes to deliver bactericides to bacterial biofilms. Methods Enzymol. 2005;391:211-28. PubMed PMID: 15721384. 11: Wang L, Liu YM, Li Y. Comparison of F-actin fluorescent labeling methods in pollen tubes of Lilium davidii. Plant Cell Rep. 2005 Jul;24(5):266-70. Epub 2005 Mar 15. PubMed PMID: 16021524. 12: Hozumi T, Miki M, Higashi-Fujime S. Maleimidobenzoyl actin: its biochemical properties and in vitro motility. J Biochem. 1996 Jan;119(1):151-6. PubMed PMID: 8907189. 13: Wiedemann N, Pfanner N, Ryan MT. The three modules of ADP/ATP carrier cooperate in receptor recruitment and translocation into mitochondria. EMBO J. 2001 Mar 1;20(5):951-60. PubMed PMID: 11230119; PubMed Central PMCID: PMC145466. 14: Hancock DC, O'Reilly NJ, Evan GI. Synthesis of peptides for use as immunogens. Methods Mol Biol. 1998;80:69-79. PubMed PMID: 9664364. 15: Cserpán I, Udvardy A. The mechanism of nuclear transport of natural or artificial transport substrates in digitonin-permeabilized cells. J Cell Sci. 1995 May;108 ( Pt 5):1849-61. PubMed PMID: 7657709. 16: Capala J, Barth RF, Bendayan M, Lauzon M, Adams DM, Soloway AH, Fenstermaker RA, Carlsson J. Boronated epidermal growth factor as a potential targeting agent for boron neutron capture therapy of brain tumors. Bioconjug Chem. 1996 Jan-Feb;7(1):7-15. PubMed PMID: 8741985. 17: Neurath AR, Strick N, Kolbe H, Kieny MP, Girard M, Jiang S. Confronting the hypervariability of an immunodominant epitope eliciting virus neutralizing antibodies from the envelope glycoprotein of the human immunodeficiency virus type 1 (HIV-1)--II. Synthetic peptides linked to HIV-1 carrier proteins gag and nef. Mol Immunol. 1991 Sep;28(9):965-73. PubMed PMID: 1717841. 18: Barth RF, Adams DM, Soloway AH, Alam F, Darby MV. Boronated starburst dendrimer-monoclonal antibody immunoconjugates: evaluation as a potential delivery system for neutron capture therapy. Bioconjug Chem. 1994 Jan-Feb;5(1):58-66. PubMed PMID: 8199235. 19: Jiang FN, Jiang S, Liu D, Richter A, Levy JG. Development of technology for linking photosensitizers to a model monoclonal antibody. J Immunol Methods. 1990 Nov 6;134(1):139-49. PubMed PMID: 2230147. 20: Thondawada M, Wadhwani AD, S Palanisamy D, Rathore HS, Gupta RC, Chintamaneni PK, Samanta MK, Dubala A, Varma S, Krishnamurthy PT, Gowthamarajan K. An effective treatment approach of DPP-IV inhibitor encapsulated polymeric nanoparticles conjugated with anti-CD-4 mAb for type 1 diabetes. Drug Dev Ind Pharm. 2018 Jul;44(7):1120-1129. doi: 10.1080/03639045.2018.1438460. Epub 2018 Feb 21. PubMed PMID: 29430979.